KY4 Stock Overview
Engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for KY4 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥13.70 |
| 52 Week High | JP¥20.60 |
| 52 Week Low | JP¥13.60 |
| Beta | 0.22 |
| 1 Month Change | -3.52% |
| 3 Month Change | -5.52% |
| 1 Year Change | -4.20% |
| 3 Year Change | -37.73% |
| 5 Year Change | -35.98% |
| Change since IPO | 102.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| KY4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.4% | 1.9% | 2.3% |
| 1Y | -4.2% | -12.6% | 11.9% |
Return vs Industry: KY4 exceeded the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: KY4 underperformed the German Market which returned 11.9% over the past year.
Price Volatility
| KY4 volatility | |
|---|---|
| KY4 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: KY4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: KY4's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,974 | Masashi Miyamoto | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| KY4 fundamental statistics | |
|---|---|
| Market cap | €7.18b |
| Earnings (TTM) | €514.05m |
| Revenue (TTM) | €3.07b |
14.0x
P/E Ratio2.3x
P/S RatioIs KY4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KY4 income statement (TTM) | |
|---|---|
| Revenue | JP¥498.98b |
| Cost of Revenue | JP¥128.24b |
| Gross Profit | JP¥370.74b |
| Other Expenses | JP¥287.20b |
| Earnings | JP¥83.54b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 164.12 |
| Gross Margin | 74.30% |
| Net Profit Margin | 16.74% |
| Debt/Equity Ratio | 0% |
How did KY4 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield37%
Payout RatioDoes KY4 pay a reliable dividends?
See KY4 dividend history and benchmarks| Kyowa Kirin dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Mar 25 2025 |
| Days until Ex dividend | 28 days |
| Days until Dividend pay date | 60 days |
Does KY4 pay a reliable dividends?
See KY4 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 01:40 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kyowa Kirin Co., Ltd. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiro Yoshinaga | Aizawa Securities Co. Ltd. |
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |